Degarelix

Origin and Structure

Degarelix is a synthetic decapeptide GnRH receptor antagonist developed by Ferring Pharmaceuticals and approved by the U.S. FDA in December 2008 under the trade name Firmagon. Its sequence incorporates five non-natural amino acids, including D-configured residues and a 4-aminophenylalanine modified with a carbamoyl group, which together produce high-affinity, reversible blockade of the pituitary GnRH receptor. The extensive non-natural substitution pattern is what gives degarelix both its receptor specificity and its resistance to proteolytic degradation.

Degarelix was not the first GnRH antagonist — abarelix (Plenaxis) preceded it — but it was the first to achieve durable commercial success in prostate cancer after abarelix was withdrawn from the U.S. market because of anaphylactoid reactions.

Mechanism of Action — Antagonist vs Agonist

The clinical case for degarelix rests on a mechanistic contrast with the older GnRH agonist class (leuprolide, goserelin, buserelin, triptorelin). Agonists initially stimulate the GnRH receptor, producing a 7–21 day testosterone "flare" before receptor desensitization finally suppresses gonadotropin release. During that flare window, prostate cancer can transiently worsen — spinal cord compression, urinary retention, or bone pain. Standard practice is to co-administer an oral anti-androgen to cover this period.

Degarelix binds the GnRH receptor competitively and reversibly, blocking endogenous GnRH from reaching it. There is no flare. Testosterone levels fall to castrate range (<50 ng/dL) within 3 days in over 95% of patients in the registration trials, compared to the 2–4 weeks required with leuprolide. LH and FSH suppression is similarly rapid.

Clinical Evidence

The pivotal CS21 trial (Klotz et al., published 2008 in BJU International) randomized 610 men with prostate cancer to degarelix or leuprolide over 12 months. Degarelix achieved castrate testosterone by day 3 in 96% of patients versus essentially zero percent on leuprolide. Both drugs reached equivalent testosterone suppression by day 28. PSA declines were faster and larger on degarelix during the first two weeks.

Subsequent analyses suggested degarelix may produce fewer cardiovascular events than GnRH agonists in men with pre-existing cardiovascular disease, though this signal is debated. The PRONOUNCE trial (2021), designed to test this hypothesis prospectively in ~545 patients, was terminated early for low enrollment and did not definitively resolve the question.

• Advanced hormone-sensitive prostate cancer. Primary indication — particularly useful when rapid testosterone suppression is clinically urgent.
• Patients with high disease burden. Men with spinal metastases or impending cord compression benefit from flare avoidance.
• Pre-radiotherapy hormone suppression. Short-term cytoreduction before radiation therapy.

Practical Considerations

Degarelix is administered as a subcutaneous depot injection — a 240 mg loading dose split into two injections, then 80 mg monthly maintenance. The depot forms a gel at the injection site that releases drug over 28 days. Local injection-site reactions (erythema, nodule formation, pain) occur in a substantial minority of patients, particularly with the loading dose, and are the most commonly reported adverse event. Systemic side effects mirror the GnRH agonist class: hot flashes, fatigue, weight gain, decreased libido, and longer-term bone density loss.

The Bottom Line

Degarelix is the modern answer to a specific problem in GnRH-targeted therapy: how to achieve androgen suppression without an initial flare. Its narrow indication, monthly injection schedule, and injection-site reactions have kept it a specialist rather than a first-line choice for most uncomplicated prostate cancer cases, where leuprolide's quarterly or six-monthly dosing remains more convenient. The 2020 FDA approval of relugolix (an oral GnRH antagonist) has further reshaped the competitive landscape. Degarelix nonetheless remains the canonical injectable antagonist and a useful reference point for understanding how receptor pharmacology translates into clinical differentiation.